Banner
Identification
Name Cosyntropin
Accession Number DB01284
Type biotech
Groups approved
Description

A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex.
Protein structure No_structure_small
Protein chemical formula C136H210N40O31S
Protein average weight 2933.4370
Sequences 
>ACTH(1-24)
SYSMEHFRWGKPVGKKRRPVKVYP

FASTA
Synonyms
Tetracosactide
Salts Not Available
Brand names
Name Company
Cortrosyn
Synacthen depot
Brand mixtures Not Available
Categories
  • Diagnostic Agents
CAS number 16960-16-0
Taxonomy
Kingdom Not Available
Classes Not Available
Substructures Not Available
Pharmacology
Indication For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
Pharmacodynamics Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N- terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residue. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of Cosyntropin is similar to that of purified natural ACTH. It has been established that 0.25 mg of Cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. Cosyntropin has less immunogenic activity than ACTH because the amino acid sequence having most of the antigenic activity of ACTH, i.e., amino acids 25-39, is not present in cosyntropin. The extra-adrenal effects which natural ACTH and Cosyntropin have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance.
Mechanism of action Cosyntropin combines with a specific receptor in the adrenal cell plasma membrane and, in patients with normal adrenocortical function, stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of the substrate within the mitochondria. Cosyntropin does not significantly increase plasma cortisol concentration in patients with primary or secondary adrenocortical insufficiency.
Absorption Rapidly absorbed following intramuscular administration.
Volume of distribution Not Available
Protein binding Not Available
Metabolism
Not Available
Route of elimination Not Available
Half life About 15 minutes following intravenous administration.
Clearance Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers
  • Amphastar pharmaceuticals inc
  • Bioniche pharma usa llc
  • Sandoz canada inc
Packagers
Dosage forms
Form Route Strength
Liquid Intramuscular
Powder, for solution Intravenous
Prices
Unit description Cost Unit
Cortrosyn 0.25 mg vial 127.9 USD vial
Cosyntropin 0.25 mg/ml 119.91 USD ml
Cosyntropin 0.25 mg vial 115.1 USD vial
Synacthen Depot 1 mg/vial 34.77 USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents Not Available
Properties
State solid
Experimental Properties Not Available
References
Synthesis Reference Not Available
General Reference Not Available
External Links
Resource Link
PharmGKB PA164749052 Link_out
Drug Product Database 22381 Link_out
RxList http://www.rxlist.com/cgi/generic/cortrosyn.htm Link_out
Drugs.com http://www.drugs.com/cdi/cosyntropin.html Link_out
Wikipedia http://en.wikipedia.org/wiki/Cosyntropin Link_out
ATC Codes
  • H01AA02
AHFS Codes
  • 68:28.00
PDB Entries Not Available
FDA label Not Available
MSDS Not Available
Interactions
Drug Interactions Searched, but no interactions found.
Food Interactions Not Available
Targets

1. Adrenocorticotropic hormone receptor

Pharmacological action: yes
Actions: antagonist

Receptor for ACTH. This receptor is mediated by G proteins (G(s)) which activate adenylate cyclase

Organism class: human
UniProt ID: Q01718 Link_out
Gene: MC2R Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Schwerin M, Kanitz E, Tuchscherer M, Brussow KP, Nurnberg G, Otten W: Stress-related gene expression in brain and adrenal gland of porcine fetuses and neonates. Theriogenology. 2005 Mar 1;63(4):1220-34. Pubmed
  2. Mehrabani PA, Bassett JR: Adrenocorticotropin binding sites in rat cardiac tissue. Pharmacol Biochem Behav. 1990 Jan;35(1):99-103. Pubmed
  3. Moraes RB, Czepielewski MA, Friedman G: Cortisol variation after low-dose Cortrosyn test. Crit Care Med. 2010 Jul;38(7):1612-3. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
Comments
Drug created on May 23, 2007 21:46 / Updated on September 03, 2011 16:33